Document Detail

Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.
MedLine Citation:
PMID:  21251994     Owner:  NLM     Status:  Publisher    
BACKGROUND: Treprostinil is an intravenous prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH). Few studies have compared the pharmacodynamics and effectiveness of treprostinil and epoprostenol in patients with high-risk PAH. METHODS: Case series of patients with PAH admitted to a Medical Intensive Care Unit for transition from epoprostenol to intravenous treprostinil for refractory class III-IV functional symptoms or right heart failure. Mixed linear models were used for comparisons between repeated hemodynamic measurements. RESULTS: Five of fourteen patients treated with intravenous treprostinil during the study period underwent transition to epoprostenol. Two had PAH associated with systemic sclerosis, three had idiopathic PAH. Pulmonary arterial pressures (PAP) and pulmonary vascular resistance significantly increased within 1 h after discontinuation of treprostinil in all subjects. Mean PAPs immediately prior to discontinuation of treprostinil (53.4 ± 7.5 mmHg) were significantly lower than the values 1 h after discontinuation (63.6 ± 9.6 mmHg, p = 0.026), but were significantly higher than the values following transition to epoprostenol (45.4 ± 5.5, p = 0.0493); 4/5 subjects had short-term clinical follow-up data available; all improved in functional class. No subject experienced adverse events during the transition. CONCLUSIONS: High-risk PAH patients with an inadequate response to treprostinil may have significant clinical and hemodynamic response to epoprostenol. Following discontinuation of treprostinil in these patients, the hemodynamic effects of discontinuation were seen in substantially shorter time than what is known to be the pharmacokinetic terminal half-life.
Allan J Walkey; Daniel Fein; Kevin J Horbowicz; Harrison W Farber
Related Documents :
9284264 - Association of toxic shock syndrome toxin-secreting and exfoliative toxin-secreting sta...
7639414 - Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in ma...
11177654 - Stress echocardiography in the diagnosis of coronary artery disease.
1957754 - Recovery-phase patterns of st segment depression in the heart rate domain cannot distin...
11916444 - Coronary artery bypass grafting in an adult case with kawasaki disease.
7733734 - Subclavian artery branch ligation reduces hemorrhage during resection of pulmonary aspe...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-1-18
Journal Detail:
Title:  Pulmonary pharmacology & therapeutics     Volume:  -     ISSN:  1522-9629     ISO Abbreviation:  -     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-1-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9715279     Medline TA:  Pulm Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier Ltd.
The Pulmonary Center, Boston University School of Medicine, 715 Albany Street, R-304, Boston, MA 02118-2394, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inhaled corticosteroids may have a beneficial effect on bone metabolism in newly diagnosed asthmatic...
Next Document:  [Allergic fungal rhinosinusitis caused by Curvularia sp.].